Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Allergic Contact Dermatitis
Interventions: Patch tests; Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Chondral Defect, Articular Cartilage Defect
Interventions: autologous cultured chondrocytes on porcine collagen membrane, Bone Marrow Stimulation; Biological · Procedure
Lead sponsor: Vericel Corporation; Industry
Eligibility: 17 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Gilbert, Arizona • Castro Valley, California • Sacramento, California + 9 more

Conditions: Smoking Cessation, Smoking Reduction, Smoking, Tobacco
Interventions: Cessation Intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: conventional surgery, cryosurgery; Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronary Artery Disease (CAD)
Interventions: Heartflow PCI Navigator; Diagnostic Test
Lead sponsor: HeartFlow, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Metastatic Spine Lesions
Interventions: single-fraction radiation, MRI and/or CT; Radiation · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastasis From Malignant Tumor of Prostate (Disorder)
Interventions: 64Cu-PSMA I&T; Drug
Lead sponsor: Curium US LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: New Haven, Connecticut • Hines, Illinois • Baltimore, Maryland + 3 more

Conditions: Smoking Cessation
Interventions: Combination NRT (Nicotine patch, Nicotine lozenge), Varenicline, Placebo, Intensive smoking counseling; Drug · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 822 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sudden Cardiac Arrest
Interventions: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD); Device
Lead sponsor: Element Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 30
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Hartford, Connecticut + 25 more

Conditions: Pterygium
Interventions: Ranibizumab; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Schizophrenia, Psychopathology, Nicotine Dependence
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Malignant Liver Neoplasm
Interventions: Ablation Therapy, Image-Guided Therapy, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiac Arrhythmia
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anal Cancer
Interventions: Self-sampling, Nylon-flocked Swab; Behavioral · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 35 Years and older
Enrollment: 572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Houston, Texas • Milwaukee, Wisconsin

Conditions: Melanoma
Interventions: Nivolumab, HF10; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Melanoma
Interventions: Skin Self Examination Information and ABCDE Rule; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 3
States / cities: Chicago, Illinois • Maywood, Illinois • Lebanon, New Hampshire

Conditions: Acne Vulgaris
Interventions: CD2475/101 40 mg, Doxycycline 100 mg, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more

Conditions: Obesity, Overweight, Cigarette Smoking
Interventions: semaglutide 2.4mg, Placebo, Nicotine Replacement Therapy (NRT, nicotine patch), Brief Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Austin, Texas • Houston, Texas

Conditions: Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions: Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic, Non Malignant Pain
Interventions: EN3270; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Berlin, New Jersey

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Unresectable Solid Tumor, Metastatic Cancer
Interventions: Proton GRID Radiotherapy; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Basal Cell Carcinoma
Interventions: Photodynamic Therapy (PDT), Metvix cream, Placebo Cream; Radiation · Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 9
States / cities: Santa Monica, California • Minneapolis, Minnesota • Rochester, Minnesota + 6 more

Conditions: Post-ERCP Pancreatitis
Interventions: Use of different concentrations of oxygen during ERCP; Procedure
Lead sponsor: Syed Z. Ali, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Immune Reactions in Contact Dermatitis Affected Skin

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

Tobacco Cessation in Public Housing

Cryosurgery in Treating Women With Breast Lesions

The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI

Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Genetically Informed Smoking Cessation Trial

The Jewel IDE Study

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study

Patient Status Engine (PSE): EARLY FEASIBILITY AND USABILITY STUDY

Self-sampling to Optimize Anal Lesion Outcomes

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Partner Assistance in Learning and Performing Skin Self-Examination

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

Semaglutide for Post-Smoking Cessation Weight Management

Cardiometabolic Consequences of the Loss of Ovarian Function

Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma

Effects of High FIO2 on Post-ERCP Pancreatitis.